Publications

  1. Wong WW, Anderson EM, Mohammadi H, Daniels TB, Schild SE, Keole SR, Choo CR, Tzou KS, Bryce AH, Ho TH, Quevedo FJ, Vora SA. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Dec; 15 (6):e969-e975 Epub 2017 Apr 26
    View PubMed
  2. Schild MH, Schild SE, Wong WW, Vora SA, Keole SR, Vargas CE, Daniels TB, Ezzell GA, Nguyen BD, Roarke MC. A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT. Int J Radiat Oncol Biol Phys. 2017 Apr 01; 97: (5)1021-1025.
    View PubMed
  3. Liu X, Li J, Schild SE, Schild MH, Wong W, Vora S, Herman MG, Fatyga M. Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther. 2017 Feb; 8 (2):73-85 Epub 2017 Feb 06
    View PubMed
  4. Rayfield C, Grady F, Jackson P, Bendok BR, Vora S, Swanson K. Clustering of Patients With GBM on Treatment Response Reveals Underlying Phenotypic Differences. Int J Radiat Oncol Biol Phys. 2016 Oct 1; 96: (2S)E65-E66.
    View PubMed
  5. Liu X, Li J, Wu T, Schild SE, Schild MH, Wong W, Vora S, Fatyga M. Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade >= 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol. 2016 Jun; 5: (3).
    View PubMed
  6. Liu X, Fatyga M, Herman M, Vora S, Wong W, Schild S, Schild M, Li J, Wu T. SU-D-204-03: Comparison of Patient Positioning Methods Through Modeling of Acute Rectal Toxicity in Intensity Modulated Radiation Therapy for Prostate Cancer. Does Quality of Data Matter More Than the Quantity? Med Phys. 2016 Jun; 43: (6)3332.
    View PubMed
  7. Liu X, Fatyga M, Li J, Schild M, Schild S, Vora S, Wong W, Wu T. TH-AB-304-02: Fitting Grade>=2(2+) Acute Rectal Complication Rates in Prostate Cancer Patients to Lyman Kutcher Burman (LKB) and Logistic Regression NTCP Models Using Dosimetry and Patient Specific Characteristics. Med Phys. 2015 Jun; 42(6):3700.
    View PubMed
  8. Liu W, Liao Z, Schild SE, Liu Z, Li H, Li Y, Park PC, Li X, Stoker J, Shen J, Keole S, Anand A, Fatyga M, Dong L, Sahoo N, Vora S, Wong W, Zhu XR, Bues M, Mohan R. Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. Pract Radiat Oncol. 2015 Mar-Apr; 5: (2)e77-86.
    View PubMed
  9. Rule WG, Foster NR, Meyers JP, Ashman JB, Vora SA, Kozelsky TF, Garces YI, Urbanic JJ, Salama JK, Schild SE. Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol. 2015 Mar; 6 (2):119-26 Epub 2014 Dec 04
    View PubMed
  10. Schild MH, Schild SE, Wong WW, Vora SA, Silva AC, Silva AC, Daniels TB, Keole SR. Early Outcome of Prostate Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Intra-Prostatic MRI Directed Boost. OMICS J Radiol. 2014 Dec; 3: (4).
    View PubMed
  11. Schild SE, Rule WG, Ashman JB, Vora SA, Keole S, Anand A, Liu W, Bues M. Proton beam therapy for locally advanced lung cancer: A review. World J Clin Oncol. 2014 Oct 10; 5: (4)568-75.
    View PubMed
  12. Wong WW, Pockaj BA, Vora SA, Halyard MY, Gray RJ, Schild SE. Six-year outcome of a prospective study evaluating tumor bed boost with intra-operative electron irradiation followed by whole-breast irradiation for early-stage breast cancer. Breast J. 2014 Mar-Apr; 20(2):125-30. Epub 2013 Dec 26.
    View PubMed
  13. Wisenbaugh ES, Andrews PE, Ferrigni RG, Schild SE, Keole SR, Wong WW, Vora SA. Proton beam therapy for localized prostate cancer 101: basics, controversies, and facts. Rev Urol. 2014; 16: (2)67-75.
    View PubMed
  14. Vora SA, Wong WW, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. J Urol. 2013 Aug; 190(2):521-6. Epub 2013 Feb 13.
    View PubMed
  15. Paripati HR, Karlin NJ, Schild SE, Vora SA, Dueck AC, Ross HJ. Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer-A retrospective analysis. Journal of Geriatric Oncology. 2012; 3(2):104-10.
  16. Wong WW, Schild SE, Vora SA, Ezzell GA, Nguyen BD, Ram PC, Roarke MC. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81 (4):e423-9 Epub 2011 Apr 07
    View PubMed
  17. Wong WW, Vora SA, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer. 2009 Dec 1; 115(23):5596-606.
    View PubMed
  18. Nguyen BD, Schild SE, Wong WW, Vora SA. Prostate brachytherapy seed embolization to the right renal artery. Brachytherapy. 2009 Jul-Sep; 8: (3)309-12.
    View PubMed
  19. Schild S, Graham D, Hillman S, Vora S, Yolanda G, Molina J, Shahidi H, Kugler J, Adjei A. Survival of patients (pts) treated with high-dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC). J Clin Oncol. 2009 May 20; 27: (15_suppl)7544.
    View PubMed
  20. Schild MH, Wong WW, Vora SA, Ward LD, Nguyen BD. Embolization of an iodine-125 radioactive seed from the prostate gland into the right ventricle: An unusual pattern of seed migration. Radiography. 2009; 15(2):179-81.
    View PubMed
  21. Lyons MK, Vora SA. Brain tumors: current issues in diagnosis and management. Semin Neurol. 2007 Sep; 27(4):312-24.
    View PubMed
  22. Vora SA, Wong WW, Schild SE, Ezzell GA, Halyard MY. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1053-8. Epub 2007 Mar 29.
    View PubMed
  23. Halyard MY, Jatoi A, Sloan JA, Bearden JD, Vora SA, Atherton PJ, Perez EA, Soori G, Zalduendo AC, Zhu A, Stella PJ, Loprinzi CL. Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys. 2007 Apr 1; 67(5):1318-22.
    View PubMed
  24. Schild SE, Wong WW, Vora SA, Halyard MY, Northfelt DW, Kogut HL, Wheeler RH. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005 Aug 1; 62(5):1432-7.
    View PubMed
  25. Schwartz DJ, Schild SE, Wong WW, Vora SA. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005 Jan 1; 61(1):60-3.
    View PubMed
  26. MacDonald OK, Schild SE, Vora S, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK, Wong WW. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology. 2004 Oct; 64(4):760-4.
    View PubMed
  27. Wong WW, Schild SE, Vora SA, Halyard MY. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Sep 1; 60(1):24-9.
    View PubMed
  28. Schild SE, Korte SM, Wong WW, Vora SA, Younggren JA, Ezzell GA. Treatment planning for dose escalation in non-small cell lung cancer (NSCLC). Med Dosim. 2004 Fall; 29(3):196-203.
    View PubMed
  29. Halyard MY, McCombs KE, Wong WW, Buchel EW, Pockaj BA, Vora SA, Gray RJ, Schild SE. Acute and chronic results of adjuvant radiotherapy after mastectomy and Transverse Rectus Abdominis Myocutaneous (TRAM) flap reconstruction for breast cancer. Am J Clin Oncol. 2004 Aug; 27(4):389-94.
    View PubMed
  30. Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK, Wong WW. Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2004 Apr 1; 58(5):1530-5.
    View PubMed
  31. Vora SA, Garner SL. Role of radiation therapy for facial skin cancers. Clin Plast Surg. 2004 Jan; 31(1):33-8.
    View PubMed
  32. Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK, Wong WW. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol. 2003 Nov; 170(5):1833-7.
    View PubMed
  33. Schild SE, Wong WW, Vora SA, Halyard MY, Wheeler RH. Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Nov 1; 54(3):729-34.
    View PubMed
  34. Serago CF, Chungbin SJ, Buskirk SJ, Ezzell GA, Collie AC, Vora SA. Initial experience with ultrasound localization for positioning prostate cancer patients for external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53: (5)1130-8.
    View PubMed
  35. Safran H, Moore T, Iannitti D, Dipetrillo T, Akerman P, Cioffi W, Harrington D, Quirk D, Rathore R, Cruff D, Vakharia J, Vora SA, Savarese D, Wanebo H. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. International Journal Radiation Oncology Biol Physics. 2001; 49(5):1275-9.
  36. Vora SA, Daly BD, Blaszkowsky L, McGrath JJ, Bankoff M, Supran S, Dipetrillo TA. High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma. Cancer. 2000 Nov 1; 89(9):1946-52.
    View PubMed
  37. Vora SA, Wazer DE, Homer MJ. Management of microcalcifications that develop at the lumpectomy site after breast-conserving therapy. Radiology. 1997 Jun; 203(3):667-71.
    View PubMed
  38. Mangan DF, Novak MJ, Vora SA, Mourad J, Kriger PS. Lectinlike interactions of Fusobacterium nucleatum with human neutrophils. Infection & Immunity. 1989 Nov; 57(11):3601-11.
    View PubMed